Stay updated with breaking news from Aduhelm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
THURSDAY, Dec. 29, 2022 (HealthDay News) -- The U.S. Food and Drug Administration's approval process for the controversial Alzheimer's drug Aduhelm was "rife with irregularities," despite lingering doubts about the
THURSDAY, Dec. 29, 2022 (HealthDay News) -- The U.S. Food and Drug Administration approval process for the controversial Alzheimer drug Aduhelm was "rife with irregularities," despite lingering doubts about the
The U.S. Food and Drug Administration's (FDA) approval process of the controversial and costly new Alzheimer’s drug Aduhelm was "rife with irregularities" ...
The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
The investigation found that Biogen knew the drug's hefty price tag would make the medication inaccessible to many patients.